Barclays PLC Has $402,000 Stock Holdings in AVITA Medical, Inc. (NASDAQ:RCEL)

Barclays PLC lifted its holdings in shares of AVITA Medical, Inc. (NASDAQ:RCELFree Report) by 340.0% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 37,503 shares of the company’s stock after buying an additional 28,979 shares during the period. Barclays PLC owned about 0.14% of AVITA Medical worth $402,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of RCEL. Rhumbline Advisers grew its position in AVITA Medical by 13.9% in the second quarter. Rhumbline Advisers now owns 36,530 shares of the company’s stock valued at $289,000 after acquiring an additional 4,463 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of AVITA Medical in the 2nd quarter valued at approximately $86,000. Essex Investment Management Co. LLC bought a new stake in shares of AVITA Medical during the 3rd quarter valued at approximately $2,477,000. Huntington National Bank acquired a new position in AVITA Medical during the 3rd quarter worth approximately $32,000. Finally, Quest Partners LLC lifted its stake in AVITA Medical by 269.4% in the 3rd quarter. Quest Partners LLC now owns 7,520 shares of the company’s stock valued at $81,000 after purchasing an additional 5,484 shares during the last quarter. Institutional investors and hedge funds own 27.66% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on RCEL shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 target price on shares of AVITA Medical in a research note on Tuesday, December 24th. D. Boral Capital started coverage on AVITA Medical in a report on Tuesday, December 24th. They set a “buy” rating and a $25.00 price objective on the stock. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $12.00 target price (up previously from $9.00) on shares of AVITA Medical in a report on Friday, November 8th.

View Our Latest Stock Analysis on AVITA Medical

AVITA Medical Stock Up 3.5 %

NASDAQ:RCEL opened at $13.24 on Friday. The company has a debt-to-equity ratio of 3.48, a current ratio of 3.73 and a quick ratio of 3.37. AVITA Medical, Inc. has a one year low of $7.51 and a one year high of $18.93. The firm’s 50 day simple moving average is $12.42 and its 200 day simple moving average is $10.49. The company has a market cap of $347.13 million, a PE ratio of -5.94 and a beta of 1.60.

AVITA Medical (NASDAQ:RCELGet Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.21). The business had revenue of $19.55 million during the quarter, compared to the consensus estimate of $19.65 million. AVITA Medical had a negative return on equity of 194.69% and a negative net margin of 95.47%. During the same period in the prior year, the firm earned ($0.34) EPS. On average, research analysts anticipate that AVITA Medical, Inc. will post -2.35 earnings per share for the current year.

AVITA Medical Company Profile

(Free Report)

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.

Further Reading

Institutional Ownership by Quarter for AVITA Medical (NASDAQ:RCEL)

Receive News & Ratings for AVITA Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA Medical and related companies with MarketBeat.com's FREE daily email newsletter.